February 17, 2022
1 min watch
Save
VIDEO: Teprotumumab efficacy sustained after 6 months in thyroid eye disease
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
AUSTIN, Texas — In this Healio Video Perspective from the North American Neuro-Ophthalmology Society meeting, Prem Subramanian, MD, PhD, discusses the sustained efficacy of teprotumumab in patients with thyroid eye disease.
Published by:
Sources/Disclosures
Collapse
Source:
Prem Subramanian, MD, PhD
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.